139 related articles for article (PubMed ID: 10026902)
1. A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma.
Rainov NG; Sena-Esteves M; Fraefel C; Dobberstein KU; Chiocca EA; Breakefield XO
Adv Exp Med Biol; 1998; 451():393-403. PubMed ID: 10026902
[TBL] [Abstract][Full Text] [Related]
2. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol.
Rainov NG; Dobberstein KU; Sena-Esteves M; Herrlinger U; Kramm CM; Philpot RM; Hilton J; Chiocca EA; Breakefield XO
Hum Gene Ther; 1998 Jun; 9(9):1261-73. PubMed ID: 9650611
[TBL] [Abstract][Full Text] [Related]
3. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy.
Frank S; Steffens S; Fischer U; Tlolko A; Rainov NG; Kramm CM
Cancer Gene Ther; 2002 Feb; 9(2):178-88. PubMed ID: 11857036
[TBL] [Abstract][Full Text] [Related]
4. Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: applications for prodrug-activating gene therapy.
Steffens S; Frank S; Fischer U; Heuser C; Meyer KL; Dobberstein KU; Rainov NG; Kramm CM
Cancer Gene Ther; 2000 May; 7(5):806-12. PubMed ID: 10830728
[TBL] [Abstract][Full Text] [Related]
5. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma.
Mohr L; Rainov NG; Mohr UG; Wands JR
Cancer Gene Ther; 2000 Jul; 7(7):1008-14. PubMed ID: 10917203
[TBL] [Abstract][Full Text] [Related]
6. Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter.
Hsu H; Rainov NG; Quinones A; Eling DJ; Sakamoto KM; Spear MA
Anticancer Res; 2003; 23(3B):2723-8. PubMed ID: 12894565
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
Chen L; Waxman DJ
Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
[TBL] [Abstract][Full Text] [Related]
8. 4-Ipomeanol and 2-aminoanthracene cytotoxicity in C3H/10T1/2 cells expressing rabbit cytochrome P450 4B1.
Smith PB; Tiano HF; Nesnow S; Boyd MR; Philpot RM; Langenbach R
Biochem Pharmacol; 1995 Nov; 50(10):1567-75. PubMed ID: 7503758
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of a 18F-labeled 4-ipomeanol as an imaging agent for CYP4B1 gene prodrug activation therapy.
Moon BS; Jang SJ; Kim SJ; Lee TS; Chi DY; Lee BC; Kang JH; Kim SE
Cancer Biother Radiopharm; 2013 Oct; 28(8):588-97. PubMed ID: 23682585
[TBL] [Abstract][Full Text] [Related]
10. Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo.
Aboody-Guterman KS; Pechan PA; Rainov NG; Sena-Esteves M; Jacobs A; Snyder EY; Wild P; Schraner E; Tobler K; Breakefield XO; Fraefel C
Neuroreport; 1997 Dec; 8(17):3801-8. PubMed ID: 9427374
[TBL] [Abstract][Full Text] [Related]
11. Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression.
Jacobs A; Dubrovin M; Hewett J; Sena-Esteves M; Tan CW; Slack M; Sadelain M; Breakefield XO; Tjuvajev JG
Neoplasia; 1999 Jun; 1(2):154-61. PubMed ID: 10933050
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors.
Vincent AJ; Vogels R; Someren GV; Esandi MC; Noteboom JL; Avezaat CJ; Vecht C; Bekkum DW; Valerio D; Bout A; Hoogerbrugge PM
Hum Gene Ther; 1996 Jan; 7(2):197-205. PubMed ID: 8788170
[TBL] [Abstract][Full Text] [Related]
13. Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes.
Jacobs AH; Winkeler A; Hartung M; Slack M; Dittmar C; Kummer C; Knoess C; Galldiks N; Vollmar S; Wienhard K; Heiss WD
Hum Gene Ther; 2003 Feb; 14(3):277-97. PubMed ID: 12639307
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+.
Doloff JC; Su T; Waxman DJ
BMC Cancer; 2010 Sep; 10():487. PubMed ID: 20836875
[TBL] [Abstract][Full Text] [Related]
16. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Jounaidi Y; Hecht JE; Waxman DJ
Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a canine glioma cell line as related to established experimental brain tumor models.
Rainov NG; Koch S; Sena-Esteves M; Berens ME
J Neuropathol Exp Neurol; 2000 Jul; 59(7):607-13. PubMed ID: 10901232
[TBL] [Abstract][Full Text] [Related]
18. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.
Schwartz PS; Chen CS; Waxman DJ
Cancer Res; 2002 Dec; 62(23):6928-37. PubMed ID: 12460909
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells.
Rubsam LZ; Boucher PD; Murphy PJ; KuKuruga M; Shewach DS
Cancer Res; 1999 Feb; 59(3):669-75. PubMed ID: 9973216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
